NCT03726281View on ClinicalTrials.gov

Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 1, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Germ Cell Tumors
Interventions
DRUG

Nivolumab

Nivolumab 240 mg, IV

Trial Locations (1)

2674-514

Hospital Beatriz Ângelo, Loures

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Universidade Nova de Lisboa

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Instituto de Patologia e Imunologia Molecular da Universidade do Porto

UNKNOWN

lead

Hospital Beatriz Ângelo

OTHER

NCT03726281 - Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors | Biotech Hunter | Biotech Hunter